secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001193125-25-129494
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Taysha Gene Therapies Announces FDA Alignment on Pivotal Part B Trial Design for TSHA-102 in Rett Syndrome
--------------------------------------------------------------------------------

- 100% of 10 patients in Part A gained/regained ≥1 developmental milestone post-TSHA-102, with ~0% likelihood from natural history data.
- FDA supports single-arm open-label pivotal trial (N=15) with primary endpoint of developmental milestone gain/regain in patients ≥6 years.
- High dose outperformed low dose, with dose-dependent effects deepening over time; no treatment-related SAEs or DLTs.
- Analysis of IRSF natural history study (N~1100) showed patients ≥6 years in developmental plateau, <6.7% likelihood of milestone gain.
- Company expects to submit protocol this quarter and initiate pivotal trial in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/0001193125-25-129494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-129494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer